DNA demethylation of promoter region orchestrates SPI‐1‐induced ADAMTS‐5 expression in articular cartilage of osteoarthritis mice

Abstract

AbstractOsteoarthritis (OA) is one of the most prevalent joint diseases in aged people and characterized by articular cartilage degeneration, synovial inflammation, and abnormal bone remodeling. Recent advances in OA research have clearly shown that OA development is associated with aberrant DNA methylation status of many OA‐related genes. As one of most important cartilage degrading proteases in OA, a disintegrin and metalloproteinase with thrombospondin motifs subtype 5 (ADAMTS‐5) is activated to mediate cartilage degradation in human OA and experimental murine OA models. The pathological factors and signaling pathways mediating ADAMTS‐5 activation during OA development are not well defined and have been a focus of intense research. ADAMTS‐5 promoter is featured by CpG islands. So far there have been no reports concerning the DNA methylation status in ADAMTS‐5 promoter during OA development. In this study, we sought to investigate DNA methylation status in ADAMTS‐5 promoter, the role of DNA methylation in ADAMTS‐5 activation in OA, and the underlying mechanisms. The potential for anti‐OA intervention therapy which is based on modulating DNA methylation is also explored. Our results showed that DNA methyltransferases 1 (Dnmt1) downregulation‐associated ADAMTS‐5 promoter demethylation played an important role in ADAMTS‐5 activation in OA, which facilitated SPI‐1 binding on ADAMTS‐5 promoter to activate ADAMTS‐5 expression. More importantly, OA pathological phenotype of mice was alleviated in response to Dnmt1‐induced DNA methylation of ADAMTS‐5 promoter. Our study will benefit not only for deeper insights into the functional role and regulation mechanisms of ADAMTS‐5 in OA, but also for the discovery of disease‐modifying OA drugs on the basis of ADAMTS‐5 via modulating DNA methylation status.